MHRA has licensed brensocatib as the first drug for non-cystic fibrosis bronchiectasis in patients aged 12 and older. This small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) is being developed by Insmed Incorporated, a global biopharmaceutical company. Brensocatib is designed to treat bronchiectasis and other neutrophil-mediated diseases, such as chronic rhinosinusitis without nasal polyps (CRSsNP). Insmed's pipeline also includes ARIKAYCE (amikacin liposome inhalation suspension), a commercial product used to treat Mycobacterium avium complex (MAC) lung disease in adult patients with limited or no alternative treatment options. Additionally, the company is developing TPIP, an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which is targeted at pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
